Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK

被引:1
作者
Fornacon-Wood, I. [1 ]
Banfill, K. [1 ,2 ]
Ahmad, S. [3 ]
Britten, A. [4 ]
Carson, C. [5 ]
Dorey, N. [6 ]
Hatton, M. [7 ]
Hiley, C. [8 ]
Jayaprakash, K. Thippu [9 ]
Jegannathen, A. [10 ]
Kidd, A. C. [11 ]
Koh, P. [12 ]
Panakis, N. [13 ]
Peedell, C. [14 ]
Peters, A. [15 ]
Pope, A. [16 ]
Powell, C. [17 ]
Stilwell, C. [18 ]
Thomas, B. [19 ]
Toy, E. [20 ]
Wicks, K. [1 ,2 ]
Wood, V. [21 ]
Yahya, S. [22 ]
Price, G. [1 ,2 ]
Faivre-Finn, C. [1 ,2 ]
机构
[1] Univ Manchester, Manchester, England
[2] Christie NHS Fdn Trust, Manchester, England
[3] Guys & St ThomasNHS Fdn Trust, London, England
[4] Brighton & Sussex Univ Hosp NHS Trust, Brighton, England
[5] Northern Ireland Canc Ctr, Belfast, North Ireland
[6] Torbay & South Devon NHS Fdn Trust, Torquay, England
[7] Weston Pk Hosp, Sheffield, S, England
[8] Univ Coll London Hosp, London, England
[9] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Cambridge, England
[10] Univ Hosp North Midlands, Stoke On Trent, England
[11] Singleton Hosp, Swansea, Wales
[12] Royal Wolverhampton NHS Trust, Wolverhampton, England
[13] Oxford Univ Hosp NHS Trust, Oxford, England
[14] James Cook Univ Hosp, Middlesbrough, England
[15] Beatson West Scotland Canc Ctr, Glasgow, Scotland
[16] Clatterbridge Canc Ctr, Liverpool, England
[17] Velindre Canc Ctr, Cardiff, Wales
[18] Aberdeen Royal firmary, Aberdeen, Scotland
[19] Swansea Bay Univ Hosp, Swansea, Wales
[20] Royal Devon & Exeter NHS Fdn Trust, Exeter, Devon, England
[21] Univ Hosp Southampton NHS Fdn Trust, Southampton, England
[22] Univ Hosp Birmingham, Birmingham, England
关键词
Chemotherapy; COVID-19; hypofractionation; lung cancer; radiotherapy; reduced fractionation; HYPOFRACTIONATED RADIOTHERAPY; FRACTIONATION; CHEMOTHERAPY;
D O I
10.1016/j.clon.2023.07.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: Previous work found that during the first wave of the COVID-19 pandemic, 34% of patients with lung cancer treated with curative-intent radiotherapy in the UK had a change to their centre's usual standard of care treatment (Banfill et al. Clin Oncol 2022;34:19-27). We present the impact of these changes on patient outcomes.Materials and methods: The COVID-RT Lung database was a prospective multicentre UK cohort study including patients with stage I-III lung cancer referred for and/or treated with radical radiotherapy between April and October 2020. Data were collected on patient demographics, radiotherapy and systemic treatments, toxicity, relapse and death. Multivariable Cox and logistic regression were used to assess the impact of having a change to radiotherapy on survival, distant relapse and grade >= 3 acute toxicity. The impact of omitting chemotherapy on survival and relapse was assessed using multivariable Cox regression.Results: Patient and follow-up forms were available for 1280 patients. Seven hundred and sixty-five (59.8%) patients were aged over 70 years and 603 (47.1%) were female. The median follow-up was 213 days (119, 376). Patients with stage I-II non-small cell lung cancer (NSCLC) who had a change to their radiotherapy had no significant increase in distant relapse (P 1/4 0.859) or death (P 1/4 0.884); however, they did have increased odds of grade >= 3 acute toxicity (P 1/4 0.0348). Patients with stage III NSCLC who had a change to their radiotherapy had no significant increase in distant relapse (P = 0.216) or death (P = 0.789); however, they did have increased odds of grade >= 3 acute toxicity (P < 0.001). Patients with stage III NSCLC who had their chemotherapy omitted had no significant increase in distant relapse (P = 0.0827) or death (P = 0.0661).Conclusion: This study suggests that changes to radiotherapy and chemotherapy made in response to the COVID-19 pandemic did not significantly affect distant relapse or survival. Changes to radiotherapy, namely increased hypofractionation, led to increased odds of grade >= 3 acute toxicity. These results are important, as hypofractionated treatments can help to reduce hospital attendances in the context of potential future emergency situations. (c) 2023 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
引用
收藏
页码:E593 / E600
页数:8
相关论文
共 21 条
[1]   Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer [J].
Auperin, Anne ;
Le Pechoux, Cecile ;
Rolland, Estelle ;
Curran, Walter J. ;
Furuse, Kiyoyuki ;
Fournel, Pierre ;
Belderbos, Jose ;
Clamon, Gerald ;
Ulutin, Hakki Cuneyt ;
Paulus, Rebecca ;
Yamanaka, Takeharu ;
Bozonnat, Marie-Cecile ;
Uitterhoeve, Apollonia ;
Wang, Xiaofei ;
Stewart, Lesley ;
Arriagada, Rodrigo ;
Burdett, Sarah ;
Pignon, Jean-Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2181-2190
[2]   Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK [J].
Banfill, K. ;
Croxford, W. ;
Fornacon-Wood, I ;
Wicks, K. ;
Ahmad, S. ;
Britten, A. ;
Carson, C. ;
Dorey, N. ;
Hatton, M. ;
Hiley, C. ;
Jayaprakash, K. Thippu ;
Jegannathen, A. ;
Koh, P. ;
Panakis, N. ;
Peedell, C. ;
Pope, A. ;
Powell, C. ;
Stilwell, C. ;
Thomas, B. ;
Toy, E. ;
Wood, V ;
Yahya, S. ;
Zhou, S. Y. ;
Price, G. ;
Faivre-Finn, C. .
CLINICAL ONCOLOGY, 2022, 34 (01) :19-27
[3]   Improving Outcomes in NSCLC: Optimum Dose Fractionation in Radical Radiotherapy Matters [J].
Brada, Michael ;
Forbes, Helen ;
Ashley, Susan ;
Fenwick, John .
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) :532-543
[4]   The National Lung Cancer Audit: The Impact of COVID-19 [J].
Conibear, J. ;
Nossiter, J. ;
Foster, C. ;
West, D. ;
Cromwell, D. ;
Navani, N. .
CLINICAL ONCOLOGY, 2022, 34 (11) :701-707
[5]   Evidence-based Estimates of the Demand for Radiotherapy [J].
Delaney, G. P. ;
Barton, M. B. .
CLINICAL ONCOLOGY, 2015, 27 (02) :70-76
[6]   Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic [J].
Faivre-Finn, C. ;
Fenwick, J. D. ;
Franks, K. N. ;
Harrow, S. ;
Hatton, M. Q. F. ;
Hiley, C. ;
McAleese, J. J. ;
McDonald, F. ;
O'Hare, J. ;
Peedell, C. ;
Pope, T. ;
Powell, C. ;
Rulach, R. ;
Toy, E. .
CLINICAL ONCOLOGY, 2020, 32 (08) :481-489
[7]   Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial [J].
Faivre-Finn, Corinne ;
Snee, Michael ;
Ashcroft, Linda ;
Appel, Wiebke ;
Barlesi, Fabrice ;
Bhatnagar, Adityanarayan ;
Bezjak, Andrea ;
Cardenal, Felipe ;
Fournel, Pierre ;
Harden, Susan ;
Le Pechoux, Cecile ;
McMenemin, Rhona ;
Mohammed, Nazia ;
O'Brien, Mary ;
Pantarotto, Jason ;
Surmont, Veerle ;
Van Meerbeeck, Jan P. ;
Woll, Penella J. ;
Lorigan, Paul ;
Blackhall, Fiona .
LANCET ONCOLOGY, 2017, 18 (08) :1116-1125
[8]   Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status A Randomized Clinical Trial [J].
Iyengar, Puneeth ;
Zhang-Velten, Elizabeth ;
Court, Laurence ;
Westover, Kenneth ;
Yan, Yulong ;
Lin, Mu-Han ;
Xiong, Zhenyu ;
Patel, Mehul ;
Rivera, Douglas ;
Chang, Joe ;
Saunders, Mark ;
Shivnani, Anand ;
Lee, Andrew ;
Hughes, Randall ;
Gerber, David ;
Dowell, Jonathan ;
Gao, Ang ;
Heinzerling, John ;
Li, Ying ;
Ahn, Chul ;
Choy, Hak ;
Timmerman, Robert .
JAMA ONCOLOGY, 2021, 7 (10) :1497-1505
[9]   What is the optimal radiotherapy utilization rate for lung cancer? -a systematic review [J].
Liu, Wei ;
Liu, Alissa ;
Chan, Jessica ;
Boldt, R. Gabriel ;
Munoz-Schuffenegger, Pablo ;
Louie, Alexander, V .
TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 :S163-S171
[10]   SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status [J].
Maguire, J. ;
Khan, I. ;
McMenemin, R. ;
O'Rourke, N. ;
McNee, S. ;
Kelly, V. ;
Peedell, C. ;
Snee, M. .
EUROPEAN JOURNAL OF CANCER, 2014, 50 (17) :2939-2949